Effects of Vitamin D Supplementation on Testosterone, Prostate, and Lower Urinary Tract Symptoms: A Prospective, Comparative Study

Overview

Journal World J Mens Health

Date 2023 Jan 17

PMID 36649925

Authors

Jeong Kyun Yeo

Sun Gu Park

Min Gu Park

Affiliations

Soon will be listed here.

Abstract

Purpose: Several studies have associated the serum vitamin D level with total testosterone levels and the prostate volume. Herein, we investigated the effect of vitamin D supplementation on testosterone, prostate, and lower urinary tract symptoms (LUTS) in men.

Materials And Methods: Men over 40 years of age diagnosed with a vitamin D deficiency (25[OH]D <20 ng/mL) who received vitamin D supplementation for one year were included in the study and administered 25,000 IU of cholecalciferol every 2 weeks. Prostate ultrasound, uroflowmetry, postvoid residual urine volume measurement, and serological tests (serum testosterone levels, ) were performed upon diagnosis and one year later. Participants also answered the International Prostate Symptom Score (IPSS) and Aging Males' Symptoms Scale (AMS) questionnaires.

Results: A significant increase was observed in the vitamin D level following one year of vitamin D supplementation, with a significant decrease in the postvoid residual urine volume, total IPSS score and without a significant change in the prostate volume. Improved psychological subscale score of AMS questionnaire was observed with a statistical significance.

Conclusions: Vitamin D supplementation suppressed the increase in the prostate volume and improved the LUTS. Although there is no direct effect on serum testosterone levels, vitamin D supplementation helped improve hypogonadal symptoms.

Citing Articles

The Impact of Vitamin D on Androgens and Anabolic Steroids among Adult Males: A Meta-Analytic Review.

Abu-Zaid A, Saleh S, Adly H, Baradwan S, Alharran A, Alhatm M Diseases. 2024; 12(10).

PMID: 39452471 PMC: 11506788. DOI: 10.3390/diseases12100228.

Safety and Efficacy Assessment of Red Ginseng Oil (RXGIN) in Men with Lower Urinary Tract Symptoms in a Randomized, Double-Blind, Placebo-Controlled Trial.

Shin D, Yoon B, Bang S, Bae W, Ha U, Kim S World J Mens Health. 2023; 42(1):229-236.

PMID: 37652660 PMC: 10782132. DOI: 10.5534/wjmh.230172.

References

Wang N, Han B, Li Q, Chen Y, Chen Y, Xia F . Vitamin D is associated with testosterone and hypogonadism in Chinese men: Results from a cross-sectional SPECT-China study. Reprod Biol Endocrinol. 2015; 13:74. PMC: 4504177. DOI: 10.1186/s12958-015-0068-2. View

Park S, Yeo J, Cho D, Park M . Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia. Aging Male. 2017; 21(1):55-59. DOI: 10.1080/13685538.2017.1311857. View

Morelli A, Vignozzi L, Filippi S, Vannelli G, Ambrosini S, Mancina R . BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate. 2006; 67(3):234-47. DOI: 10.1002/pros.20463. View

Kim H, Cho M . Low Serum 25-Hydroxyvitamin D Level as a Potential Risk Factor of Erectile Dysfunction in Elderly Men with Moderate to Severe Lower Urinary Tract Symptoms. World J Mens Health. 2021; 40(1):139-148. PMC: 8761244. DOI: 10.5534/wjmh.200176. View

Gutierrez-Robledo L, Avila-Funes J, Amieva H, Meillon C, Acosta J, Navarrete-Reyes A . Association of low serum 25-hydroxyvitamin D levels with the frailty syndrome in Mexican community-dwelling elderly. Aging Male. 2015; 19(1):58-63. DOI: 10.3109/13685538.2015.1105796. View

Costanzo P, Suarez S, Kozak A, Knoblovits P . Seasonal Variations in Sex Steroids in a Young Male Population and Their Relationship with Plasma Levels of Vitamin D. World J Mens Health. 2021; 40(2):308-315. PMC: 8987141. DOI: 10.5534/wjmh.200156. View

Faul F, Erdfelder E, Lang A, Buchner A . G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007; 39(2):175-91. DOI: 10.3758/bf03193146. View

Pittas A, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K . Systematic review: Vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010; 152(5):307-14. PMC: 3211092. DOI: 10.7326/0003-4819-152-5-201003020-00009. View

Kinuta K, Tanaka H, Moriwake T, Aya K, Kato S, Seino Y . Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinology. 2000; 141(4):1317-24. DOI: 10.1210/endo.141.4.7403. View

10.

Tak Y, Lee J, Kim Y, Park N, Kim S, Lee S . Serum 25-hydroxyvitamin D levels and testosterone deficiency in middle-aged Korean men: a cross-sectional study. Asian J Androl. 2014; 17(2):324-8. PMC: 4650484. DOI: 10.4103/1008-682X.142137. View

11.

Pilz S, Frisch S, Koertke H, Kuhn J, Dreier J, Obermayer-Pietsch B . Effect of vitamin D supplementation on testosterone levels in men. Horm Metab Res. 2010; 43(3):223-5. DOI: 10.1055/s-0030-1269854. View

12.

Crescioli C, Maggie M, Vannelli G, Luconi M, Salerno R, Barni T . Effect of a vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostate hyperplasia. J Clin Endocrinol Metab. 2000; 85(7):2576-83. DOI: 10.1210/jcem.85.7.6690. View

13.

Lerchbaum E, Trummer C, Theiler-Schwetz V, Kollmann M, Wolfler M, Heijboer A . Effects of vitamin D supplementation on androgens in men with low testosterone levels: a randomized controlled trial. Eur J Nutr. 2018; 58(8):3135-3146. PMC: 6842386. DOI: 10.1007/s00394-018-1858-z. View

14.

Melamed M, Michos E, Post W, Astor B . 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008; 168(15):1629-37. PMC: 2677029. DOI: 10.1001/archinte.168.15.1629. View

15.

Yoo S, Oh S, Kim H, Choi H, Park J, Cho S . Impact of serum 25-OH vitamin D level on lower urinary tract symptoms in men: a step towards reducing overactive bladder. BJU Int. 2018; 122(4):667-672. DOI: 10.1111/bju.14387. View

16.

Wu P, Rhew E, Dyer A, Dunlop D, Langman C, Price H . 25-hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Rheum. 2009; 61(10):1387-95. PMC: 2785856. DOI: 10.1002/art.24785. View

17.

Lerchbaum E, Pilz S, Trummer C, Schwetz V, Pachernegg O, Heijboer A . Vitamin D and Testosterone in Healthy Men: A Randomized Controlled Trial. J Clin Endocrinol Metab. 2017; 102(11):4292-4302. DOI: 10.1210/jc.2017-01428. View

18.

Heijboer A, Oosterwerff M, Schroten N, Eekhoff E, Chel V, de Boer R . Vitamin D supplementation and testosterone concentrations in male human subjects. Clin Endocrinol (Oxf). 2015; 83(1):105-10. DOI: 10.1111/cen.12711. View

19.

Penna G, Fibbi B, Amuchastegui S, Corsiero E, Laverny G, Silvestrini E . The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate. 2008; 69(5):480-93. DOI: 10.1002/pros.20896. View

20.

Blomberg Jensen M, Nielsen J, Jorgensen A, Rajpert-De Meyts E, Kristensen D, Jorgensen N . Vitamin D receptor and vitamin D metabolizing enzymes are expressed in the human male reproductive tract. Hum Reprod. 2010; 25(5):1303-11. DOI: 10.1093/humrep/deq024. View